Reevaluation by High-Performance Liquid Chromatography: Clinical Significance of Microalbuminuria in Individuals at High Risk of Cardiovascular Disease in the Heart Outcomes Prevention Evaluation (HOPE) Study

American Journal of Kidney Diseases

Volumn 48, Issue 6, 2006, Pages 889-896

  McQueen, Matthew J ^a   Gerstein, Hertzel C ^a   Pogue, Janice ^a   Mann, Johannes F E ^a   Yusuf, Salim ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

cardiovascular risk; high performance liquid chromatography; Microalbuminuria; radioimmunoassay

Indexed keywords

ALBUMIN; CREATININE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DEATH; DIABETES MELLITUS; FEMALE; HEART INFARCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RISK PATIENT; HUMAN; IMMUNOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NORTH AMERICA; PREVALENCE; PREVENTIVE MEDICINE; PROTEIN URINE LEVEL; RADIOIMMUNOASSAY; RECEIVER OPERATING CHARACTERISTIC; STORAGE TEMPERATURE; STROKE;

ALBUMINURIA; CARDIOVASCULAR DISEASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETIC NEPHROPATHIES; FEMALE; HEART DISEASES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; RADIOIMMUNOASSAY; REGRESSION ANALYSIS; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY; SMOKING;

EID: 33845434334     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.09.003     Document Type: Article

References (22)

1. HOPE Study Investigators: The HOPE (Heart Outcomes Prevention Evaluation) Study. The design of a large, simple randomized trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 12 (1996) 127-137
2. Gerstein H.C., Bosch J., Pogue J., Wayne Taylor D., Zinman B., Yusuf S., and HOPE Study Investigators. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes: The MICRO-HOPE Study. Diabetes Care 19 (1996) 1225-1228
3. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. Lancet 255 (2000) 253-259
4. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
5. Mann J.F.E., Gerstein H.C., Qilong Y., et al. Development of renal disease in people at high cardiovascular risk; Results of the HOPE randomized study. J Am Soc Nephrol 14 (2003) 641-647
6. Gerstein H.C., Mann J.F.E., Pogue J., et al. Prevalence and determinants of microalbuminuria in high-risk diabetic and non-diabetic patients in the Heart Outcomes Prevention Evaluation Study. Diabetes Care 23 suppl 2 (2000) SB35-SB39
7. Gerstein H.C., Mann J.F.E., Qilong Y., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non-diabetic individuals. JAMA 286 (2001) 421-426
8. de Zeeuw D. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?. Kidney Int Suppl 92 (2004) S2-S6
9. Burne M.J., Panagiotopoulos C., Jerums G., and Comper W.D. Alterations in the renal degradation of albumin in early experimental diabetes: A new factor in the mechanism of albuminuria. Clin Sci 95 (1998) 67-72
10. Osicka T.M., Houlihan C.A., Chan J.G., Jerums G., and Comper W.D. Albuminuria in patients with type 1 diabetes is directly linked to changes in the lysosome-mediated degradation of albumin during renal passage. Diabetes 49 (2000) 1579-1584
11. Grieve K.A., Balazs N.D.H., and Comper W.D. Protein fragments in urine have been considerably underestimated by various protein assays. Clin Chem 47 (2001) 1717-1719
12. Eppel G.A., Nagy S., Jenkins M.A., et al. Variability of standard clinical protein assays in the analysis of a model urine solution of fragmented albumin. Clin Biochem 33 (2000) 487-494
13. Wiggins R.C., Kshrisazer B., Kelsch R.C., and Wilson B.S. Fragmentation and polymeric complexes of albumin in human urine. Clin Chim Acta 1489 (1985) 155-163
14. Yagame M., Suzuki D., Jinde K., et al. Urinary albumin fragments as a new clinical parameter for the early detection of diabetic nephropathy. Int Med 34 (1995) 463-468
15. Comper W.D., Osicka T.M., and Jerums G. High prevalence of immuno-unreactive intact albumin in urine of diabetic patients. Am J Kidney Dis 41 (2003) 336-341
16. Comper W.D., Osicka T.M., Clark M., MacIsaac R.J., and Jerums G. Earlier detection of microalbuminuria in diabetic patients using a new urinary albumin assay. Kidney Int 65 (2004) 1850-1855
17. Osicka T.M., and Comper W.D. Characterization of immunochemically nonreactive urinary albumin. Clin Chem 12 (2004) 2286-2291
18. Peters Jr. T. New form of urinary albumin in early diabetes. Clin Chem 12 (2004) 2238-2239
19. Mann J.F.E., Qilong Y., and Gerstein H.C. Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. Kidney Int Suppl 2 (2004) S59-S62
20. Brinkman J.W., Bakker S.J.L., Gansevoort R.T., et al. Which method for quantifying urinary albumin excretion gives what outcome?. A comparison of immunonephelometry with HPLC. Kidney Int Suppl 92 (2004) S69-S75
21. Polkinghorne K.R., Su Q., Chadban S.J., Shaw J.E., Zimmet P.Z., and Atkins R.C. Population prevalence of albuminuria in the Australian Diabetes, Obesity, and Lifestyle (AusDiab) Study: Immunonephelometry compared with high-performance liquid chromatography. Am J Kidney Dis 47 (2006) 604-613
22. Owen W.E., and Roberts W.L. Performance characteristics of an HPLC assay for urinary albumin. Am J Clin Pathol 124 (2005) 219-225